THERAPY DOSSIER · th-6dbe2983a752

Cerium oxide nanoparticles, formulations CNP-18 and CNP-ME

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27135969 ↗2016Mixed findings

Cerium Oxide Nanoparticles: A Potential Medical Countermeasure to Mitigate Radiation-Induced Lung Injury in CBA/J Mice.

MouseRadiationCBA/JFemalen = 10 per groupIntraperitonealLow dose 100 nM (0.00007 mg/kg) and high dose 10 microM (0.…First dose 2 h after irradiation

Model: Single 15 Gy whole-thorax irradiation at a dose rate of 69 cGy/min (320 kVp, 10 mA, HVL 1.00 mm Cu)

High-dose CNP-18 increased survival to 90 per cent versus 10 per cent with radiation alone and reduced fibrosis, inflammation and vascular damage, whereas low-dose CNP-18 and both CNP-ME doses gave limited benefit.

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…